|
Jun 16
|
Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics
|
|
Feb 12
|
Roivant Sciences price target lowered to $12 from $13 at BofA
|
|
Feb 12
|
News Flash: Analysts Just Made A Captivating Upgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) Forecasts
|
|
Jan 29
|
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025
|